Company news

Xeris Biopharma Holdings, Inc. news in 2024

Xeris Biopharma Holdings, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference

November 25, 2024

Xeris Biopharma Reports Third Quarter 2024 Financial Results

November 7, 2024

Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024

October 30, 2024

Xeris Biopharma Reports Second Quarter 2024 Financial Results

August 7, 2024

Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024

July 24, 2024

Xeris Biopharma Announces CEO Succession Plan

July 7, 2024

Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024

June 2, 2024

Xeris to Participate in the Jefferies Global Healthcare Conference

May 29, 2024

Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)

May 29, 2024

Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events

May 8, 2024

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics

May 5, 2024

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics

May 5, 2024

Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024

May 1, 2024

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024

Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital

March 5, 2024

Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events

March 5, 2024

Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

February 27, 2024

Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference

February 4, 2024

Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab

January 9, 2024

Xeris Biopharma Updates Its Outlook for 2023

January 3, 2024

Calls in 2024